WPI 845 (Glipizide extended release 10 mg)
Pill imprint WPI 845 has been identified as Glipizide extended release 10 mg.
Glipizide is used in the treatment of diabetes, type 2 and belongs to the drug class sulfonylureas. Risk cannot be ruled out during pregnancy. Glipizide 10 mg is not subject to the Controlled Substances Act.
See also related documents.
Images for WPI 845 (Glipizide extended release 10 mg)
- 10 mg
- 6.00 mm
- Prescription only
- Drug Class:
- Pregnancy Category:
- C - Risk cannot be ruled out
- CSA Schedule:
- N - Not a controlled drug
- Watson Laboratories, Inc.
- National Drug Code (NDC):
- Inactive Ingredients:
- acetyltributyl citrate
hydroxyethyl cellulose (2000 mpa.s at 1%)
hydroxypropyl cellulose (type h)
methacrylic acid - methyl methacrylate copolymer (1:1)
|NDC Code||Manufacturer / Repackager|
|68084-0112||Amerisource Health Services|
|54569-5548||A S Medication Solutions LLC (repackager)|
|54868-4988||Physicians Total Care Inc (repackager)|
|58016-0691||Southwood Pharmaceuticals Inc (repackager)|
|55887-0179||Diversified Healthcare Services Inc (repackager)|
|55289-0301||PDRX Pharmaceuticals Inc (repackager)|
Note: Inactive ingredients may vary.